Adverse Events and Tolerability of Combined Durvalumab and Tremelimumab versus Durvalumab Alone in Solid Cancers: A Systematic Review and Meta-Analysis

Adverse Events and Tolerability of Combined Durvalumab and Tremelimumab versus Durvalumab Alone in Solid Cancers: A Systematic Review and Meta-Analysis

Background: Recently, the combination of durvalumab and tremelimumab, two immune checkpoint inhibitors, for the treatment of different types of cancers has been considered; however, its overall effects, including its safety, are still unclear and need to be further investigated. Objectives: The aim...

وصف كامل

التفاصيل البيبلوغرافية
المؤلفون الرئيسيون: Omar Fahmy, Osama A. A. Ahmed, Mohd Ghani Khairul-Asri, Nabil A. Alhakamy, Waleed S. Alharbi, Usama A. Fahmy, Mohamed A. El-Moselhy, Claudia G. Fresta, Giuseppe Caruso, Filippo Caraci
التنسيق: مقال
اللغة:English
منشور في: MDPI AG 2022-05-01
سلاسل:Biomedicines
الموضوعات:
durvalumab
tremelimumab
combined therapy
monotherapy
checkpoint inhibitors
adverse effects
الوصول للمادة أونلاين:https://www.mdpi.com/2227-9059/10/5/1101

الانترنت

https://www.mdpi.com/2227-9059/10/5/1101

مواد مشابهة